Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Vol. 29, 16 January 2024
* Author to whom correspondence should be addressed.
Gastrointestinal cancers, including esophageal, gastric, hepatic, pancreatic, and colorectal malignancies, present a significant global health challenge. Their distinct characteristics characterized by abnormal cell proliferation, invasive behavior, and tumor formation make them highly aggressive and detrimental to human health. These diseases often lead to malnutrition, organ failure, and obstruction. Cyclin D1 protein is a critical regulator of cell cycle progression and an essential marker for comprehending the complex landscape of cancer biology. This research provides an in-depth exploration of gastrointestinal cancers by shedding light on their adverse effects on the human body while emphasizing the critical role played by cyclin D1 within this challenging disease context. Extensively studied in colorectal cancer as well as esophageal squamous cell carcinoma (ESCC), gastric cancer, and pancreatic cancer contexts. Cyclin D1 emerges as a key player. Specifically, in cases of colorectal cancer, overexpression of cyclin D1 is frequently linked to aggressive tumor behavior brought on by APC gene mutations and abnormal Wnt signalling pathway activation. Esophageal cancer patients especially those with ESCC frequently exhibit elevated levels of Cyclin D1 indicating poor prognosis. A similar trend is observed in gastric cancer where increased expression of cyclin D1 is linked to disease severity.
gastrointestinal cancers, esophageal cancer, gastric cancer, cyclin D1
1. Murphy N, Jenab M, Gunter M J. 2018 Nature Reviews Gastroenterology & Hepatology 15(11) 659-670
2. O’Connor M J, Thakar T, Nicolae C M, et al. 2021 Oncogene 40(30) 4872-4883
3. Montalto F I, De Amicis F. 2020 Cells 9(12) 2648
4. Huang F L, Yu S J. 2018 Asian journal of surgery 41(3) 210-215
5. Smyth E C, Nilsson M, Grabsch H I, et al. 2020 The Lancet 396(10251) 635-648
6. Dekker E, Tanis P J, Vleugels J L A, et al. 2019 Lancet 394(10207)1467-1480
7. Thanikachalam K, Khan G. 2019 Nutrients 11(1) 164
8. Weitz J, Koch M, Debus J, et al. 2005 Lancet 365(9454) 153-165
9. Tchakarska G, Sola B. 2020 Cell cycle 19(2) 163-178
10. Kontomanolis E N, Koutras A, Syllaios A, et al. 2021 J. BU ON Off. J. Balk. Union Oncol. 26 1723-1734
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).